Pancreatosteatosis in Patients with Adrenal Incidentaloma: a Risk Factor for Impaired Glucose Metabolism

Burcu Candemir,Kadir Kisip,Şafak Akın,Hatice Tuba Sanal,Mustafa Taşar,Bülent Altunkaynak,Neşe Ersöz Gülçelik
DOI: https://doi.org/10.1016/j.diabres.2024.111099
IF: 8.18
2024-01-21
Diabetes Research and Clinical Practice
Abstract:Aims Patients with adrenal incidentaloma (AI) are at increased risk of impaired glucose metabolism, which is known to be associated with pancreatosteatosis (PS). We aimed to investigate the risk of developing dysglycemia for patients with non-functioning AI (NFAI) versus those without, and whether the presence of PS predicts future dysglycemia in patients with NFAI. Method In 80 patients with NFAI and 127 controls matched for age, sex, and body mass index, changes in fasting plasma glucose (FPG) and hemoglobin A1c(HbA1c) were evaluated at 2 years. PS was evaluated with data obtained from non-contrast abdominal computed tomography (CT) performed at the initial evaluation. Results Mean FPG levels increased significantly after 2 years in both groups ( P < 0.001, for both), albeit significantly higher among patients than the controls ( P =0.002). The increases in HbA1c and FPG levels were significantly higher among patients with PS than without PS, in the adenoma group (p<0.001, P =0.00, respectively). The change in Hba1c levels was associated with the presence of PS in patients with NFAI (p<0.001). Conclusions Our findings suggest that the presence of PS may provide significant information in predicting newly developed dysglycemia in patients with NFAI.
endocrinology & metabolism
What problem does this paper attempt to address?